Our researchers are investigating genetic variants associated with IBD, particularly focusing on rare variants with potentially greater functional effects. This work spans genome-wide association studies as well as identifying specific mutations and their consequences in disease pathogenesis. Our researchers are exploring how genetic variations affect various cellular pathways, including reactive oxygen species pathways, and autophagy processes.

Researchers in this area include:

• Judy Cho, MD, PhD

Our microbiome research focuses on understanding how variations in gut microbiome composition affect IBD susceptibility and progression. Our scientists are exploring the role of the microbiome in intestinal inflammation, studying interactions between the host immune system and microbes at the epithelial cell surface and within the gut lumen. Some of our studies specifically examine disease transmission potential through microbiome changes during pregnancy, and how these might affect newborns.

Researchers in this area include:

• Jeremiah Faith, PhD
• Jose C. Clemente, PhD
• Sergio Lira, MD, PhD
• Inga Peter, PhD

Our researchers continue to conduct randomized controlled trials comparing different biological agents, exploring triple combination therapies, and investigating the maintenance role of specific drugs in achieving and maintaining remission in severe IBD cases.

Researchers in this area include:

• Jean-Frederic Colombel, MD
• Bruce E. Sands, MD, MS
• Saurabh Mehandru, MD
• Marla C. Dubinsky, MD

We also study the relationship between IBD and cancer, with investigations focusing on dysplasia progression, cancer risk in IBD patients, and the safety of immunosuppressive medications in patients with a history of cancer. We maintain a focus on colorectal neoplasia detection methods and risk factors in high-risk IBD patients, especially those with Primary Sclerosing Cholangitis.

Researchers in this area include:

• Steven Itzkowitz, MD
• Thomas Ullman, MD

Our research additionally encompasses the unique challenges of pediatric IBD patients, including treatment optimization and the critical transition to adult care, alongside studies focused on specific patient subgroups. Scientists within the Division are developing personalized treatment approaches through pharmacokinetic modeling for children, assessing barriers to successful transitional care, and investigating factors affecting quality of life in various populations.

Researchers in this area include:

• Marla C. Dubinsky, MD
• Jean-Frederic Colombel, MD
• Bruce E. Sands, MD, MS

This research area combines understanding IBD complications with efforts to prevent disease onset and progression. Our scientists are investigating intestinal strictures in Crohn's disease by analyzing their microscopic morphology and pathophysiology, identifying predictors of disease extension in ulcerative colitis, and developing predictive biomarker panels for early intervention. By studying high-risk individuals based on familial history, researchers gain insights into early disease pathogenesis, differentiating biomarkers that precede disease from those occurring as a response.

Researchers in this area include:

• Judy Cho, MD, PhD
• Jean-Frederic Colombel, MD
• Noam Harpaz, MD, PhD
• Marla Dubinsky, MD

Our immune regulation and host-pathogen studies examine immune interactions in gut inflammation, including specific cells, chemokines, and signaling pathways involved in intestinal immune responses. Our researchers are investigating cellular recruitment to the colon, differential immune responses to various gut microbiotas, and how conditions like HIV infection affect IBD through immunological mechanisms.

Researchers in this area include:

• Saurabh Mehandru, MD
• Jeremiah Faith, PhD
• Jose C. Clemente, PhD